OTCMKTS:SIGY Sigyn Therapeutics Q1 2025 Earnings Report $0.04 0.00 (0.00%) As of 06/8/2026 11:11 AM Eastern ProfileEarnings History Sigyn Therapeutics EPS ResultsActual EPS-$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASigyn Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASigyn Therapeutics Announcement DetailsQuarterQ1 2025Date5/20/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsSigyn Therapeutics' next earnings date is estimated for Tuesday, August 18, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sigyn Therapeutics Earnings HeadlinesSIGY Sigyn Therapeutics Inc.May 20, 2026 | seekingalpha.comSigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTEApril 2, 2026 | finance.yahoo.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 9 at 1:00 AM | Reagan Gold Group (Ad)Sigyn Therapeutics Delays Annual SEC FilingMarch 31, 2026 | tipranks.comScientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory DiseasesMarch 24, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale InitiativesMarch 13, 2026 | finance.yahoo.comSee More Sigyn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email. Email Address About Sigyn TherapeuticsSigyn Therapeutics (OTCMKTS:SIGY), a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.View Sigyn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?Has Temu-Owner PDD's Story Changed After Double Miss?Campbell's Soup Stock: Deep Value and a 7% Dividend YieldTanker Dividends Are Surging, But Income Investors Need to Watch the CycleCybersecurity Earnings: 1 AI Standout and 2 Stocks Under PressureThese 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
